San Diego-based mostly Viking Therapeutics marked itself as a significant competitor inside the weight loss drug industry in February just after revealing promising information from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection and in March the compan